Inhibitor of p38 kinase LY2228820 (Ralimetinib) abrogated those effects (Fig. 6g) confirming the role of p38 in ubiquitination and degradation of IFNAR1 caused by tumor-derived factors and ER stress in myeloid cells. This evidence concerns the gene IFNAR1 and neoplasm.